Show simple item record

AuthorElshafei, Mohamed Nabil
AuthorImam, Yahia
AuthorAlsaud, Arwa Ebrahim
AuthorChandra, Prem
AuthorParray, Aijaz
AuthorAbdelmoneim, Mohamed S.
AuthorObeidat, Khaldun
AuthorSaeid, Razan
AuthorAli, Mohammad
AuthorAyadathil, Raheem
AuthorMohamed, Mouhand F.H.
AuthorAbdallah, Ibtihal M.
AuthorMohammed, Shaban
AuthorAkhtar, Naveed
AuthorDanjuma, Mohammed Ibn Masoud
Available date2024-02-14T07:48:43Z
Publication Date2022-09-19
Publication NameEuropean Journal of Clinical Pharmacology
Identifierhttp://dx.doi.org/10.1007/s00228-022-03391-2
CitationElshafei, M. N., Imam, Y., Alsaud, A. E., Chandra, P., Parray, A., Abdelmoneim, M. S., ... & Danjuma, M. I. M. (2022). The impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study. European Journal of Clinical Pharmacology, 78(11), 1801-1811.
ISSN0031-6970
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85138261807&origin=inward
URIhttp://hdl.handle.net/10576/51807
AbstractBackground and purpose: Uncertainty remains regarding the impact of enteric-coated aspirin (EC-ASA) on secondary prevention of ischemic stroke compared to plain aspirin (P-ASA). Hence, this study was designed to investigate the effect of EC formulation on ASA response via evaluating thromboxane B2 (TXB2) levels in patients with suspected or newly diagnosed stroke. Methods: A prospective cohort study on suspected or newly diagnosed ischemic stroke patients who are aspirin-naive was conducted. Patients were received either EC aspirin or plain aspirin for at least 3 days. The primary outcome was the proportion of aspirin non-responsiveness between two groups (level of residual serum TXB2 associated with elevated thrombotic risk (< 99.0% inhibition or TXB2 > 3.1 ng/ml) within 72 h after three daily aspirin doses, while secondary outcomes were the incidence of early gastrointestinal tract (GIT) bleeding with the various aspirin preparations. (Trial registration: Clinicaltrials.gov NCT04330872 registered on 02 April 2020). Results: Of 42 patients, ischemic strokes were confirmed in both P-ASA (81%) and EC-ASA (67%) arms. ASA non-responsiveness showed no significant difference between the two formulations (P-ASA vs. EC-ASA; 28.6% vs 23.8%; P = 0.726). Univariate and multivariate logistic regression analysis showed that patients treated with EC-ASA were more likely to have a lower rate of non-responders compared to P-ASA (unadjusted OR 0.78; 95% CI 0.20, 3.11); with the risk highest in type 2 diabetic patients with HBA1c > 6.5% (adjusted OR 6; 95% CI 1.02, 35.27; P = 0.047). No incidence of GIT bleeding observed throughout the study. Conclusion: A significant proportion of ASA non-responsiveness was recorded regardless of ASA formulation administered. The increased risk of ASA non-responsiveness in diabetic patients needs further exploration by larger prospective studies.
SponsorOpen Access funding provided by the Qatar National Library. Besides the publication fund provided by Qatar National library (QNL), this study was supported by an internal research grant from the MRC of Hamad Medical Corporation (HMC).
Languageen
PublisherSpringer Nature
SubjectAspirin response
Enteric-coated aspirin
Plain aspirin
Stroke
Thromboxane B2
TitleThe impact of enteric coating of aspirin on aspirin responsiveness in patients with suspected or newly diagnosed ischemic stroke: prospective cohort study: results from the (ECASIS) study
TypeArticle
Pagination1801-1811
Issue Number11
Volume Number78
ESSN1432-1041


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record